Neuland Laboratories Share Price
Sector: Major Drugs
11053.20 -817.15 (-6.88%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
10598.05
Today’s High
11458.40
52 Week Low
5557.00
52 Week High
18089.55
11056.00 -803.00 (-6.77%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
10578.00
Today’s High
11469.00
52 Week Low
5540.10
52 Week High
18100.00
Key Metrics
- Market Cap (In Cr) 14181.14
- Beta 0.77
- Div. Yield (%) 0.11
- P/B 9.3
- TTM P/E 59.54
- Sector P/E 24.5
- D/E 0
- Open Price 11000.05
- Prev Close 11870.35
Neuland Laboratories Analysis
Price Analysis
-
1 Week-11.05%
-
3 Months-6.51%
-
6 Month-29.08%
-
YTD-19.44%
-
1 Year77.45%
Risk Meter
- 53% Low risk
- 53% Moderate risk
- 53% Balanced Risk
- 53% High risk
- 53% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 1
- Buy
- 1
- 1
- 1
- 1
- Hold
- 0.00
- 0.00
- 0.00
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 2
- 2
- 2
- 2
Neuland Laboratories News
Q4 results today: ITC Hotels, Cochin Shipyard, JSW Energy and more on May 15
1 min read . 15 May 2025₹61.60 to ₹11,000: Multibagger stock turns ₹1 lakh into ₹1.78 crore in 13 years
1 min read . 27 Feb 2025Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
2 min read . 28 Nov 2024Neuland Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 1476.84
- Selling/ General/ Admin Expenses Total
- 272
- Depreciation/ Amortization
- 65.55
- Other Operating Expenses Total
- 131.06
- Total Operating Expense
- 1142.72
- Operating Income
- 334.12
- Net Income Before Taxes
- 346.33
- Net Income
- 260.11
- Diluted Normalized EPS
- 158.01
- Period
- 2025
- Total Assets
- 2179.88
- Total Liabilities
- 655.08
- Total Equity
- 1524.81
- Tangible Book Valueper Share Common Eq
- 966.88
- Period
- 2025
- Cashfrom Operating Activities
- 317.38
- Cashfrom Investing Activities
- -298.16
- Cashfrom Financing Activities
- 24.96
- Net Changein Cash
- 44.36
- Period
- 2024
- Total Revenue
- 1558.58
- Selling/ General/ Admin Expenses Total
- 340.11
- Depreciation/ Amortization
- 59.38
- Other Operating Expenses Total
- 6.86
- Total Operating Expense
- 1155.23
- Operating Income
- 403.35
- Net Income Before Taxes
- 401.44
- Net Income
- 300.08
- Diluted Normalized EPS
- 248.12
- Period
- 2024
- Total Assets
- 1832.56
- Total Liabilities
- 549.86
- Total Equity
- 1282.7
- Tangible Book Valueper Share Common Eq
- 780.04
- Period
- 2024
- Cashfrom Operating Activities
- 261.18
- Cashfrom Investing Activities
- -149.69
- Cashfrom Financing Activities
- -69.28
- Net Changein Cash
- 42.16
- Period
- 2023
- Total Revenue
- 1191.2
- Selling/ General/ Admin Expenses Total
- 277.38
- Depreciation/ Amortization
- 52.46
- Other Operating Expenses Total
- 5.35
- Total Operating Expense
- 960.93
- Operating Income
- 230.27
- Net Income Before Taxes
- 215.75
- Net Income
- 163.52
- Diluted Normalized EPS
- 127.96
- Period
- 2023
- Total Assets
- 1579.76
- Total Liabilities
- 585.67
- Total Equity
- 994.1
- Tangible Book Valueper Share Common Eq
- 555.99
- Period
- 2023
- Cashfrom Operating Activities
- 237.21
- Cashfrom Investing Activities
- -61.5
- Cashfrom Financing Activities
- -135.8
- Net Changein Cash
- 40.32
- Period
- 2022
- Total Revenue
- 951.08
- Selling/ General/ Admin Expenses Total
- 253.11
- Depreciation/ Amortization
- 48.78
- Other Operating Expenses Total
- 5.63
- Total Operating Expense
- 855.59
- Operating Income
- 95.49
- Net Income Before Taxes
- 82.16
- Net Income
- 63.82
- Diluted Normalized EPS
- 50.84
- Period
- 2022
- Total Assets
- 1383.49
- Total Liabilities
- 542.99
- Total Equity
- 840.5
- Tangible Book Valueper Share Common Eq
- 435.64
- Period
- 2022
- Cashfrom Operating Activities
- 60.39
- Cashfrom Investing Activities
- -95.52
- Cashfrom Financing Activities
- 37.72
- Net Changein Cash
- 2.66
- Period
- 2021
- Total Revenue
- 936.91
- Selling/ General/ Admin Expenses Total
- 117.87
- Depreciation/ Amortization
- 39.68
- Other Operating Expenses Total
- 4.9
- Total Operating Expense
- 827.34
- Operating Income
- 109.58
- Net Income Before Taxes
- 105.33
- Net Income
- 80.63
- Diluted Normalized EPS
- 63.01
- Period
- 2021
- Total Assets
- 1324.79
- Total Liabilities
- 538.33
- Total Equity
- 786.46
- Tangible Book Valueper Share Common Eq
- 392.44
- Period
- 2021
- Cashfrom Operating Activities
- 189.36
- Cashfrom Investing Activities
- -84.42
- Cashfrom Financing Activities
- -113.66
- Net Changein Cash
- -8.77
- Period
- 2020
- Total Revenue
- 762.71
- Selling/ General/ Admin Expenses Total
- 191.03
- Depreciation/ Amortization
- 31.28
- Other Operating Expenses Total
- 3.98
- Total Operating Expense
- 690.43
- Operating Income
- 72.28
- Net Income Before Taxes
- 52.92
- Net Income
- 16.21
- Diluted Normalized EPS
- 30.53
- Period
- 2020
- Total Assets
- 1230.98
- Total Liabilities
- 521.02
- Total Equity
- 709.96
- Tangible Book Valueper Share Common Eq
- 334.02
- Period
- 2020
- Cashfrom Operating Activities
- 57.34
- Cashfrom Investing Activities
- -48.68
- Cashfrom Financing Activities
- -5.48
- Net Changein Cash
- 3.27
- Period
- 2019
- Total Revenue
- 666.83
- Selling/ General/ Admin Expenses Total
- 161.42
- Depreciation/ Amortization
- 25.86
- Other Operating Expenses Total
- 3.74
- Total Operating Expense
- 629
- Operating Income
- 37.83
- Net Income Before Taxes
- 20.34
- Net Income
- 16.44
- Diluted Normalized EPS
- 13.15
- Period
- 2019
- Total Assets
- 1130.35
- Total Liabilities
- 431.04
- Total Equity
- 699.31
- Tangible Book Valueper Share Common Eq
- 325.83
- Period
- 2019
- Cashfrom Operating Activities
- 69.91
- Cashfrom Investing Activities
- -77.23
- Cashfrom Financing Activities
- 11.98
- Net Changein Cash
- 4.65
- Period
- 2025-03-31
- Total Revenue
- 328.36
- Selling/ General/ Admin Expenses Total
- 66.46
- Depreciation/ Amortization
- 16.89
- Other Operating Expenses Total
- 38.84
- Total Operating Expense
- 294.18
- Operating Income
- 34.18
- Net Income Before Taxes
- 39.3
- Net Income
- 27.81
- Diluted Normalized EPS
- 21.67
- Period
- 2025-03-31
- Total Assets
- 2179.88
- Total Liabilities
- 655.08
- Total Equity
- 1524.81
- Tangible Book Valueper Share Common Eq
- 966.88
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 317.38
- Cashfrom Investing Activities
- -298.16
- Cashfrom Financing Activities
- 24.96
- Net Changein Cash
- 44.36
- Period
- 2024-12-31
- Total Revenue
- 398.03
- Selling/ General/ Admin Expenses Total
- 69.34
- Depreciation/ Amortization
- 16.3
- Other Operating Expenses Total
- 36.37
- Total Operating Expense
- 271.96
- Operating Income
- 126.08
- Net Income Before Taxes
- 127.76
- Net Income
- 101.59
- Diluted Normalized EPS
- 44.61
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 310.84
- Selling/ General/ Admin Expenses Total
- 63.07
- Depreciation/ Amortization
- 16.07
- Other Operating Expenses Total
- 25.79
- Total Operating Expense
- 264.69
- Operating Income
- 46.15
- Net Income Before Taxes
- 49.42
- Net Income
- 32.84
- Diluted Normalized EPS
- 25.6
- Period
- 2024-09-30
- Total Assets
- 1943.8
- Total Liabilities
- 548.59
- Total Equity
- 1395.21
- Tangible Book Valueper Share Common Eq
- 868.16
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 149.45
- Cashfrom Investing Activities
- -154.22
- Cashfrom Financing Activities
- -10.48
- Net Changein Cash
- -15.1
- Period
- 2024-06-30
- Total Revenue
- 439.6
- Selling/ General/ Admin Expenses Total
- 73.14
- Depreciation/ Amortization
- 16.28
- Other Operating Expenses Total
- 30.07
- Total Operating Expense
- 311.9
- Operating Income
- 127.71
- Net Income Before Taxes
- 129.84
- Net Income
- 97.87
- Diluted Normalized EPS
- 64.16
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 385.01
- Selling/ General/ Admin Expenses Total
- 62.49
- Depreciation/ Amortization
- 16.46
- Other Operating Expenses Total
- 35.58
- Total Operating Expense
- 294.56
- Operating Income
- 90.45
- Net Income Before Taxes
- 92.2
- Net Income
- 67.56
- Diluted Normalized EPS
- 52.66
- Period
- 2024-03-31
- Total Assets
- 1832.56
- Total Liabilities
- 549.86
- Total Equity
- 1282.7
- Tangible Book Valueper Share Common Eq
- 780.04
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 261.18
- Cashfrom Investing Activities
- -149.69
- Cashfrom Financing Activities
- -69.28
- Net Changein Cash
- 42.16
- Period
- 2023-12-31
- Total Revenue
- 392.83
- Selling/ General/ Admin Expenses Total
- 65.73
- Depreciation/ Amortization
- 15.14
- Other Operating Expenses Total
- 27.24
- Total Operating Expense
- 286.71
- Operating Income
- 106.12
- Net Income Before Taxes
- 104.48
- Net Income
- 81.39
- Diluted Normalized EPS
- 63.44
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Neuland Laboratories Technical
Moving Average
SMA
- 5 Day12107.21
- 10 Day12183.16
- 20 Day12394.06
- 50 Day11875.1
- 100 Day12663.06
- 300 Day12933.69
Neuland Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Pfizer
- 4412.6
- -43.65
- -0.98
- 6452.85
- 3742.9
- 20156.11
- Astrazeneca Pharma India
- 7839.35
- -108.25
- -1.36
- 9199
- 5180.6
- 19598.38
- Neuland Laboratories
- 11053.2
- -817.15
- -6.88
- 18089.55
- 5557
- 14181.14
- Unichem Laboratories
- 587.75
- 1.8
- 0.31
- 949.85
- 507.2
- 4137.03
- Jagsonpal Pharmaceuticals
- 213.1
- -6.3
- -2.87
- 328.02
- 109.42
- 1412.58
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Pfizer
- 36.86
- 5.62
- 18.43
- 24.05
- Astrazeneca Pharma India
- 130.35
- 27.52
- 20.1
- 10.27
- Neuland Laboratories
- 69.97
- 9.3
- 17.29
- 14.2
- Unichem Laboratories
- -
- 1.77
- -2.1
- -3.99
- Jagsonpal Pharmaceuticals
- 36.11
- 5.9
- 18
- 12.54
Neuland Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 15-May-25
- Audited Results & Final Dividend
- 10-Feb-25
- Quarterly Results
- 06-Nov-24
- Quarterly Results
- 01-Aug-24
- Quarterly Results
- 10-May-24
- Audited Results & Final Dividend
- 08-Feb-24
- Quarterly Results
- 07-Nov-23
- Quarterly Results
- 03-Aug-23
- Quarterly Results
- 11-May-23
- Audited Results & Final Dividend
- 13-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 30-Jul-25
- 15-May-25
- AGM
- 31-Jul-24
- 10-May-24
- AGM
- 27-Jul-23
- 11-May-23
- AGM
- 02-Aug-22
- 17-Jun-22
- AGM
- 07-Jul-21
- 07-Jun-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 15-May-25
- 18-Jul-25
- -
- 12
- 10-May-24
- -
- 12-Jul-24
- 14
- 11-May-23
- -
- 11-Jul-23
- 10
- 10-May-22
- 15-Jul-22
- 14-Jul-22
- 5
- 11-May-21
- -
- 29-Jun-21
- 3


